Clinical Trials Browser

Phase 1 × Liver Neoplasms × tremelimumab × Clear all

NCT05701488 2025-09-02

SIRT With Tremelimumab and Durvalumab for Resectable HCC

Phase 1 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms